Enjoy complimentary customisation on priority with our Enterprise License!
The colorectal cancer therapeutics market size is estimated to grow by USD 2.01 billion at a CAGR of 4.5% between 2023 and 2028. The aging population is a growing concern worldwide, with an increasing number of individuals entering their golden years. Simultaneously, the incidence of colorectal cancer, a prevalent form of cancer among older adults, is on the rise. To address this dual challenge, pharmaceutical companies are introducing combination therapeutics. These innovative treatments combine multiple drugs to target colorectal cancer from various angles, enhancing efficacy and reducing side effects. By harnessing the synergistic effects of multiple drugs, these combination therapies offer a promising solution to tackle the complexities of colorectal cancer in the geriatric population. This approach not only improves patient outcomes but also reduces healthcare costs by preventing multiple hospitalizations and prolonged treatments.
For More Highlights About this Report, Request Free Sample
Colorectal cancer, also known as colon or rectal cancer, is a major health concern worldwide. According to the American Cancer Society, colorectal adenocarcinoma and gastrointestinal carcinoid are the most common types of colorectal cancer. Dana-Farber and other research institutions are working on new treatments for young onset colorectal cancer. Targeted therapies, including Avastin, Erbitux, Stivarga, and immunotherapies like Keytruda, are increasingly being used in colorectal cancer treatment. These therapies target specific mutations, such as those in the KRAS gene. Hospital pharmacies, retail pharmacies, and online pharmacies are key distribution channels for colorectal cancer therapeutics. The aging population, with its increasing incidence of colorectal cancer, is a significant driver of market growth. Diagnosis rates and incident cases are also increasing, leading to a higher demand for these therapies. Thomas Wales, an oncology analyst at MSD, highlights the importance of mutation testing in determining the most effective treatment for each patient. Tyrosine kinase inhibitors from Genentech and Tecentriq from Roche are also gaining popularity in colorectal cancer therapy. Patent expiries of key drugs, such as Avastin and Erbitux, may impact market dynamics in the coming years. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing geriatric population is notably driving market growth. Colorectal cancer is a significant health concern, particularly among the aging population. According to the Centers for Disease Control and Prevention (CDC), over 90% of colorectal cancer cases occur in individuals aged 50 years and above. The World Bank and National Institutes of Health (NIH) project that the percentage of the global geriatric population will rise from 9.3% in 2020 to approximately 17% by 2050. This demographic shift is expected to result in a corresponding increase in colorectal cancer cases. Pharmaceutical companies are responding to this unmet need by developing innovative therapeutic options.
Furthermore, in oncology, there is a growing focus on immunotherapies, such as those offered by MSD with Keytruda and Genentech with Tecentriq. Mirati Therapeutics is also making strides with its Krazati and Lumakras treatments for NRAS mutants. While these therapies offer promising outcomes, they come with tolerability challenges and serious adverse events that may lead to discontinuation. Biomarkers are being explored to improve the efficacy and safety of these treatments. The high incidence of colorectal cancer and the need for more effective and tolerable therapeutic options make this a dynamic and evolving market. Chemotherapies containing tyrosine kinase inhibitors continue to be a mainstay of treatment, despite the challenges associated with their use. Thus, such factors are driving the growth of the market during the forecast period.
The development of small molecule kinase inhibitors is the key trend in the market. The market is witnessing significant advancements, with a focus on developing safe and effective treatments. While biologics, such as those from MSD with Keytruda and Genentech with Tecentriq, have dominated the market, their complex development processes, high costs, and serious adverse events have led to an unmet need for alternative treatment options. This has prompted pharmaceutical companies like Mirati Therapeutics to explore small molecule drugs that inhibit tyrosine kinases.
Furthermore, these small molecules act by inhibiting the phosphorylation of cellular substrates catalyzed by protein kinases. Deregulation of protein kinases can lead to uncontrolled cell division, inhibition of apoptosis, and other abnormalities, ultimately contributing to the development of colorectal cancer. Krazati, Lumakras, and other emerging drugs from Mirati Therapeutics are showing promise in addressing the tolerability concerns associated with chemotherapies containing NRAS mutants. Biomarkers are also being explored to improve the efficacy and safety of these treatments, with the incidence of colorectal cancer continuing to rise. Thus, such trends will shape the growth of the market during the forecast period.
Patent expiration of novel therapeutics is the major challenge that affects the growth of the market. The market is witnessing significant advancements with the introduction of novel oncology treatments. Key players in the industry, such as MSD and Genentech, have been leading the way with their innovative offerings. For instance, MSD's Keytruda, an immunotherapy, and Genentech's Tecentriq, another immunotherapy, have shown promising results in treating colorectal cancer. However, the use of tyrosine kinase inhibitors from companies like Mirati Therapeutics and their Krazati and Lumakras drugs, also hold potential in addressing the unmet need for effective colorectal cancer treatments. Despite these advancements, the market faces challenges due to the loss of patents for certain therapies.
For instance, the expiration of patents for Avastin (bevacizumab), Vectibix (panitumumab), and Zaltrap (ziv-Aflibercept) is expected to hamper market growth during the forecast period. The entry of biosimilars into the market post-patent expiration can increase competition and decrease the price of original biologic therapeutics. However, the tolerability and serious adverse events associated with chemotherapies containing these biologics can lead to discontinuation, posing a challenge for patients and healthcare providers. Additionally, the identification of biomarkers for NRAS mutants can aid in the development of targeted therapies, addressing the unmet need for effective colorectal cancer treatments. The incidence of colorectal cancer continues to rise, making the development of effective and affordable therapeutics a priority. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amgen Inc. - The company offers colorectal cancer therapeutics such as Vectibix.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the Targeted therapy segment will be significant during the forecast period. Colorectal cancer, also known as colon or rectal cancer, is a significant health concern worldwide, with colorectal adenocarcinoma being the most common type. Gastrointestinal carcinoid tumors are another less common form of colorectal cancer. Institutions like Dana-Farber Cancer Institute are at the forefront of research and treatment for young-onset colorectal cancer. Targeted therapies, such as Avastin (bevacizumab) and Erbitux (cetuximab), and immunotherapies, including Stivarga (regorafenib), have shown promise in treating colorectal cancer.
Get a glance at the market share of various regions Download the PDF Sample
The Targeted therapy segment showed a gradual increase in the market share of USD 3.17 billion in 2018. Hospitals, retail, and online pharmacies play crucial roles in providing access to these therapies. Pipeline analysis reveals ongoing research on various drugs, such as BRAFTOVI (encorafenib) for CRC patients with the BRAF V600E mutation. Other drugs in development include Cetuximab, Vectibix (panitumumab), Zakrap (sintilimab), Mvasi (bevacizumab-awwb), and biosimilars. The regulatory scenario for these therapies is evolving, with the National Library of Medicine providing updates on clinical trials and regulatory approvals. Mutation testing is essential for personalized treatment approaches, focusing on mutations like KRAS. As the aging population increases, diagnosis rates and incident cases of colorectal cancer are expected to rise. Companies like Akeda Therapeutics, Hutchmed, Roche, and others are developing novel therapies to address this growing need. Patent expiries for some drugs, such as Thomas Wales's Avastin, may also impact the market landscape.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Colorectal cancer, also known as colon or rectal cancer, is a significant health concern worldwide, with colorectal adenocarcinoma being the most common type. Gastrointestinal carcinoid tumors are less common but can also develop in the colon or rectum. Dana-Farber Cancer Institute and other research organizations continue to explore new treatments for young-onset colorectal cancer. Targeted therapies, such as Avastin (bevacizumab) and Erbitux (cetuximab), and immunotherapies, like Stivarga (regorafenib), are increasingly used in colorectal cancer treatment. Hospital pharmacies, retail pharmacies, and online pharmacies distribute these medications. Pipeline analysis indicates ongoing research on drugs like BRAFTOVI (encorafenib) for mutations like BRAF V600E. CRC, or colorectal cancer, is associated with aging and mutation testing for KRAS and microsatellite instability. Companies like Akeda Therapeutics, Hutchmed, Roche, and others are developing new drugs, such as Cotellic (cobimetinib), Fruquintinib, and Zaktrap (sintilimab). The regulatory scenario is evolving, with the National Library of Medicine providing valuable information on these drugs and their drug classes. Biosimilars are also entering the market, offering cost-effective alternatives to branded drugs. Patent expiries and Thomas Wales's research on Cetuximab and Vectibix contribute to the ongoing advancements in colorectal cancer therapeutics.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Colorectal Cancer Therapeutics Market: Colorectal Cancer Therapeutics Market by Type and Geography - Forecast and Analysis
Cancer Biologics Market: Cancer Biologics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast
Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: Cancer Biologics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast
Colorectal cancer, also known as colon or rectal cancer, is a significant health concern worldwide. Colorectal adenocarcinoma and gastrointestinal carcinoid are the most common types. Institutions like Dana-Farber and research on YoungOnset Colorectal Cancer are working towards advancements. Targeted therapies, immunotherapies, and chemotherapy are primary treatment methods. Avastin, Erbitux, Stivarga, and several others, including biosimilars like Mvasi, are essential drugs in this domain. Hospital pharmacies, retail pharmacies, and online pharmacies are crucial distribution channels.
Furthermore, pipeline analysis reveals several potential treatments, such as Akeda from Hutchmed, Roche's Cotellic, and Fruquintinib from Jiangsu Hengrui Medicine. The regulatory scenario is evolving, with the National Library of Medicine providing resources for CRC research. Mutation testing, especially for BRAF V600E, is essential for diagnosis and treatment, with drugs like BRAFTOVI and Cetuximab being effective. The aging population and increasing diagnosis rates lead to a significant incident cases count. Targeted therapies for KRAS and addressing patent expiries are key focus areas. Thomas Wales, a renowned oncologist, emphasizes the importance of continued research and innovation in colorectal cancer therapeutics.
Market Scope |
|
Report Coverage |
Details |
Page number |
146 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market Growth 2024-2028 |
USD 2.01 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.23 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key countries |
US, Germany, UK, Canada, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Accord Healthcare Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.